Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Moderna’s shares climbed in the first half of the year, as it scored victories with a product approval and solid clinical trial results. This week the biotech surprised investors with some ...

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Moderna Therapeutics (NASDAQ: MRNA) was once the darling of the healthcare space for investors. The company emerged as one of the biggest names of the COVID-19 pandemic with its vaccine.

As of 1:12 PM EDT. Market Open. Moderna stock tumbled after the company issued a light 2025 sales outlook and cut its 2027 R&D budget. Is MRNA stock a sell? These biotech stocks have what it takes ...

Who’s the iconoclastic outsider behind Summit’s success? Why can’t Moderna turn a profit? And should we be giving weight loss drugs to kids? We talk about all that and more on this week’s ...

Moderna, the Massachusetts-based biotech company that rocketed into the global spotlight during the development of its COVID-19 vaccine, announced plans on Thursday to cut costs and refocus on ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even. The Cambridge-based ...

Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1 billion, between 2024 and 2027 in a concession to investors who have viewed the company’s ...

Stocks opened and closed in positive territory, though the path to the finish line was choppy. A mixed reading on wholesale ...

Moderna Lays Out Plan to Slice Research and Development Spending Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even ...